Kidney Cancer Coverage from Every Angle
Editor:
Robert J. Motzer, MD
Advertisement
Advertisement

Recent News

CHEK2 Gene Variant Possibly Linked to Risk of Developing Clear Cell Kidney Cancer
Is Monosomy of Chromosome 9 Linked to Adverse Outcomes in Renal Cell Carcinoma?
RTK Inhibitor Plus Immunotherapy in Advanced Kidney Cancer
FDA Accepts Biologics License Application for Proposed Biosimilar To Bevacizumab
GU Cancers Symposium 2020: Novel Agent May Inhibit Oncogenic Driver in Kidney Cancer
GU Cancers Symposium 2020: Update From CheckMate 214 on First-Line Nivolumab Plus Ipilimumab for Kidney Cancer
GU Cancers Symposium 2020: Savolitinib Plus Durvalumab in Papillary Renal Carcinoma
GU Cancers Symposium 2020: Dual Immune Checkpoint Inhibition With Radiation for Kidney Cancer
GU Cancers Symposium 2020: Long-Term Data Support Nivolumab vs Everolimus in Kidney Cancer
ASCO-SITC 2020: Is Immune Primer in Renal Cell Cancer Ready for Prime Time?
Enzyme Identified as Potential Target in von Hippel-Lindau–Deficient Kidney Cancer
METEOR Trial: Age-Based Outcomes With Cabozantinib for Renal Cell Carcinoma
Later-Line Therapy for Renal Cell Carcinoma: Tivozanib Versus Sorafenib
Development of Radiomic Signatures in Renal Cell Carcinoma
FDA Grants Regulatory Approval to Expand Use of Cryoablation to Treat Kidney Cancer
IKCS 2019: Evaluating CD73 Expression in Renal Cell Tumors
IKCS 2019: Challenges of Using ctDNA in Renal Cell Carcinoma
IKCS 2019: Novel ImmunoPET/CT Under Study in Renal Cell Carcinoma
IKCS 2019: Comparing Patient- and Clinician-Reported Performance Status
IKCS 2019: Identifying a New Role for SETD2 in Clear Cell Renal Cell Carcinoma
IKCS 2019: Lenvatinib Plus Pembrolizumab in Subset of Patients With Kidney Cancer
IKCS 2019: Treatment-Free Survival With Immunotherapy Versus Sunitinib in Kidney Cancer
IKCS 2019: Histopathologic Changes Associated With Immunotherapy for Kidney Cancer
Robotic Radiosurgery for Kidney Cancer in Patients With Impaired Renal Function
First-in-Class Pegilodecakin Under Study in Advanced Renal Tumors
Could Virtual Reality Models for Surgical Planning Improve Nephrectomy Outcomes?
ESMO 2019: Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma
ESMO 2019: Enfortumab Vedotin Plus Pembrolizumab in Advanced Bladder Cancer
Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.